1 week Ago By ABMN Staff
D. Boral Capital restated their buy rating on shares of AVITA Medical ( NASDAQ:RCEL – Free Report ) in a research note released on Thursday, Benzinga reports. D.
Boral Capital currently has a $22.00 price target on the stock. RCEL has been the subject of several other reports.
Lake Street Capital cut their price target on AVITA Medical from $20.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday, January 8th.
Cantor Fitzgerald reiterated an “overweight” rating and set a $21.00 target price on shares of AVITA Medical in a research report on Tuesday, December 24th. Check Out Our Latest Stock Analysis on RCEL AVITA Medical Stock Down 0.
1 % AVITA Medical ( NASDAQ:RCEL – Get Free Report ) last released its quarterly earnings results on Thursday, February 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.
30) by ($0.14). The firm had revenue of $18.
41 million for the quarter, compared to analyst estimates of $18.40 million. AVITA Medical had a negative return on equity of 337.
91% and a negative net margin of 96.26%. As a group, equities research analysts anticipate that AVITA Medical will post -0.
95 EPS for the current fiscal year. Insider Activity In other news, Director Robert Mcnamara bought 10,000 shares of AVITA Medical stock in a transaction that occurred on Thursday, February 20th. The shares were purchased at an average price of $10.
09 per share, for a total transaction of $100,900.00. Following the completion of the acquisition, the director now owns 45,749 shares of the company’s stock, valued at $461,607.
41. The trade was a 27.97 % increase in their ownership of the stock.
The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website . Corporate insiders own 1.82% of the company’s stock.
Hedge Funds Weigh In On AVITA Medical A number of large investors have recently modified their holdings of the company. FMR LLC increased its position in AVITA Medical by 126.9% during the 3rd quarter.
FMR LLC now owns 4,248 shares of the company’s stock worth $46,000 after purchasing an additional 2,376 shares in the last quarter. State Street Corp increased its position in shares of AVITA Medical by 2.4% in the third quarter.
State Street Corp now owns 519,997 shares of the company’s stock worth $5,574,000 after acquiring an additional 11,997 shares in the last quarter. Jane Street Group LLC raised its stake in shares of AVITA Medical by 32.7% in the 3rd quarter.
Jane Street Group LLC now owns 89,395 shares of the company’s stock valued at $958,000 after acquiring an additional 22,032 shares during the period. Barclays PLC lifted its holdings in shares of AVITA Medical by 340.0% during the 3rd quarter.
Barclays PLC now owns 37,503 shares of the company’s stock valued at $402,000 after acquiring an additional 28,979 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in AVITA Medical by 1.4% during the 3rd quarter.
Geode Capital Management LLC now owns 594,436 shares of the company’s stock worth $6,373,000 after purchasing an additional 8,361 shares during the period. 27.66% of the stock is currently owned by hedge funds and other institutional investors.
About AVITA Medical ( Get Free Report ) AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. Featured Articles Receive News & Ratings for AVITA Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVITA Medical and related companies with MarketBeat.
com's FREE daily email newsletter ..
